Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
- IMbrave050 investigators
- Nanjing University of Chinese Medicine
- Sun Yat-Sen University Cancer Center
- National Taiwan University
- University of Texas MD Anderson Cancer Center
- Kindai University
- University of Ulsan
- University of Texas Southwestern Medical Center
- Fudan University
- Jilin University
- Pusan National University
- Kyungpook National University
- Japanese Red Cross Himeji Hospital
- Yokohama City University
- Hôpital Pontchaillou
- Genentech Incorporated
- Roche (China) Holding Ltd.
- National Cancer Centre
Research output: Contribution to journal › Article › peer-review
466
Scopus
citations